Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...

FDA oral Wegovy, solid fundamentals, and low P/E vs. Eli Lilly. Click for this updated look at NVO stock prospects as ...

Eli Lilly & Co slashed the price of its blockbuster weight-loss and diabetes drug Mounjaro in China, intensifying competition ...

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

The stock of Eli Lilly (LLY) is down 4% on news that rival Novo Nordisk (NVO) has begun selling its highly anticipated weight ...

Novo’s oral Wegovy launch has intensified competition for Eli Lilly heading into 2026. ・Lilly’s outlook hinges on oral drug ...

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with ...

Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline ...

TUESDAY, Jan. 6, 2026 (HealthDay News) — A daily pill for weight loss has officially arrived in the U.S. On Monday, Novo ...

Novo Nordisk introduces its new once-daily Wegovy pill in the U.S., aiming to capture a share of the competitive weight-loss drug market. Priced at $149 per month, the pill presents a needle-free ...

Novo Nordisk announced Jan. 5 it will begin offering its Wegovy weight loss pill to self-paying patients in the United States ...

Eli Lilly (LLY 3.74%) is close to doing something no other pharmaceutical company has ever done: reaching $1 trillion in ...